Ascendis Pharma A/S (NASDAQ:ASND) Given New $153.00 Price Target at TD Cowen

Ascendis Pharma A/S (NASDAQ:ASND) had its price objective trimmed by TD Cowen from $160.00 to $153.00 in a research note published on Friday morning,Benzinga reports. The firm currently has a buy rating on the biotechnology company’s stock.

Other analysts also recently issued reports about the stock. Evercore ISI increased their price objective on shares of Ascendis Pharma A/S from $191.00 to $205.00 and gave the company an “outperform” rating in a research report on Tuesday, September 17th. JPMorgan Chase & Co. cut their price target on shares of Ascendis Pharma A/S from $180.00 to $174.00 and set an “overweight” rating on the stock in a report on Wednesday, October 23rd. Wells Fargo & Company boosted their price objective on shares of Ascendis Pharma A/S from $264.00 to $289.00 and gave the stock an “overweight” rating in a report on Tuesday, September 17th. Stifel Nicolaus upped their price objective on Ascendis Pharma A/S from $200.00 to $207.00 and gave the company a “buy” rating in a research report on Friday. Finally, Wedbush reissued an “outperform” rating and issued a $181.00 target price on shares of Ascendis Pharma A/S in a report on Friday. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and twelve have issued a buy rating to the stock. Based on data from MarketBeat.com, Ascendis Pharma A/S currently has a consensus rating of “Moderate Buy” and an average price target of $191.77.

Ascendis Pharma A/S Price Performance

Shares of ASND opened at $122.00 on Friday. The company has a 50-day simple moving average of $132.40 and a two-hundred day simple moving average of $132.47. The firm has a market capitalization of $7.40 billion, a PE ratio of -15.10 and a beta of 0.66. Ascendis Pharma A/S has a one year low of $90.13 and a one year high of $161.00.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings data on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.51). The business had revenue of $38.75 million during the quarter, compared to analyst estimates of $94.74 million. Analysts expect that Ascendis Pharma A/S will post -7.3 EPS for the current fiscal year.

Hedge Funds Weigh In On Ascendis Pharma A/S

Institutional investors have recently bought and sold shares of the business. Signaturefd LLC boosted its holdings in shares of Ascendis Pharma A/S by 13.2% in the 3rd quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock worth $102,000 after purchasing an additional 80 shares during the period. Bessemer Group Inc. boosted its stake in Ascendis Pharma A/S by 61.0% during the first quarter. Bessemer Group Inc. now owns 876 shares of the biotechnology company’s stock worth $132,000 after buying an additional 332 shares during the period. Pursue Wealth Partners LLC bought a new position in Ascendis Pharma A/S during the third quarter valued at $217,000. Searle & CO. bought a new position in Ascendis Pharma A/S during the second quarter valued at $205,000. Finally, Rhumbline Advisers raised its stake in shares of Ascendis Pharma A/S by 10.3% in the second quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company’s stock valued at $209,000 after acquiring an additional 143 shares during the period.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.